US 12,326,433 B2
Abnormal cardiac rhythm myocardial model and method for producing same, agent for forming abnormal cardiac rhythm myocardial model, and method for evaluating drug efficacy of heart disease therapeutic
Michiya Matsusaki, Suita (JP); Shiro Kitano, Tokyo (JP); and Shinji Irie, Tokyo (JP)
Assigned to TOPPAN PRINTING CO., LTD., Tokyo (JP); and OSAKA UNIVERSITY, Osaka (JP)
Appl. No. 16/644,059
Filed by TOPPAN PRINTING CO., LTD., Tokyo (JP); and OSAKA UNIVERSITY, Suita (JP)
PCT Filed Sep. 3, 2018, PCT No. PCT/JP2018/032643
§ 371(c)(1), (2) Date Mar. 3, 2020,
PCT Pub. No. WO2019/045105, PCT Pub. Date Mar. 7, 2019.
Claims priority of application No. 2017-169688 (JP), filed on Sep. 4, 2017.
Prior Publication US 2021/0063374 A1, Mar. 4, 2021
Int. Cl. G01N 33/15 (2006.01); C07K 14/78 (2006.01); C12N 5/077 (2010.01)
CPC G01N 33/15 (2013.01) [C07K 14/78 (2013.01); C12N 5/0657 (2013.01)] 20 Claims
 
1. A method for evaluating drug efficacy of a heart disease therapeutic, comprising:
an administration step comprising administering the heart disease therapeutic to an abnormal cardiac rhythm myocardial model composed of a three-dimensional tissue comprising cells, wherein said cells comprise cardiomycetes and collagen, wherein said collagen comprises fragmented collagen having an average length from 100 nm to 200 μm with a triple helix structure, and said collagen is present in an amount of 0.1 mg or more relative to 1.0×105 to 10.0×105 of the cells, and wherein the abnormal cardiac rhythm myocardial model having a beating interval that changes irregularly, wherein at least a portion of the cells adheres to the collagen; and
an evaluation step comprising evaluating the drug efficacy by a change in behavior of a cardiac rhythm of the abnormal cardiac rhythm myocardial model to which the heart disease therapeutic is administered.